Global Dermatology Market History and New Update with Current Trend to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth
 |
| Dermatology |
Albany, New York, May 05, 2017
"Global
Dermatology Market to 2022 - Innovative Pipeline and Increasing
Uptake of Biologics to Diversify Treatment Options and Drive Strong
Growth"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Dermatological
conditions are one of the most common types of disorders worldwide,
and approximately one-third of the US population suffers from at
least one active skin condition.For the past decades, the majority of
the dermatology market has remained saturated with established
products. However, the clinical and commercial success of biologics
in the treatment of psoriasis, as well as advancements in the
understanding of the disease pathways of many dermatological
conditions, have led to a renewed interest from pharmaceutical
companies in the dermatology market, and subsequently the emergence
of an innovative pipeline.
Get
Sample
Report
With TOC @
http://www.researchmoz.us/enquiry.php?type=S&repid=725316
This
report covers all dermatological disorders, but there is a particular
focus on three key diseases: atopic dermatitis, acne vulgaris and
psoriasis, as these conditions have the highest prevalence and the
largest pipeline. The global dermatology market was valued at $20.0
billion in 2015, and is projected to grow at a considerable Compound
Annual Growth Rate (CAGR) of 7.73%, reaching $33.7 billion in 2022.
Key drivers of this growth will be the uptake of recently approved
premium biologics, as well as promising late-stage products that are
expected to be highly valuable.
** Scope
– The dermatology
market landscape is expected to change substantially with the advent
of promising novel pipeline products.
– Overall, there are 801 dermatology products in the pipeline, with biologics representing 37% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.
– Overall, there are 801 dermatology products in the pipeline, with biologics representing 37% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.
- Which molecular targets are most prominent within the pipeline?
- How do the key indications differ in terms of molecule type?
- How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action are most common for pipeline drugs?
– Global revenues for
the dermatology market are forecast to grow at a CAGR of 7.73%, from
$20 billion in 2015 to $33.7 billion in 2022.
- Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
- What CAGR will these companies register in the forecast period?
** Reasons to buy
– This report will
allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis.
- Visualize the composition of the dermatology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
- Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications.
- Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
- Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various dermatological conditions.
- Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.
– Table
of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
2.1 Therapy Area Introduction 10
2.2 Symptoms 10
2.3 Etiology and Pathophysiology 11
2.3.1 Atopic Dermatitis 11
2.3.2 Acne Vulgaris 12
2.3.3 Psoriasis 13
2.4 Co-morbidities and Complications 14
2.5 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 14
2.5.1 Atopic Dermatitis 15
2.5.2 Acne Vulgaris 16
2.5.3 Psoriasis 16
2.6 Treatment 17
2.6.1 Topical Corticosteroids 18
2.6.2 Calcineurin Inhibitors 19
2.6.3 Retinoids 19
2.6.4 Systemic Immunosuppressive Agents 20
2.6.5 Biologics 20
2.6.6 Antihistamines 21
2.6.7 Hormonal Therapy 21
2.6.8 Moisturizers 21
2.1 Therapy Area Introduction 10
2.2 Symptoms 10
2.3 Etiology and Pathophysiology 11
2.3.1 Atopic Dermatitis 11
2.3.2 Acne Vulgaris 12
2.3.3 Psoriasis 13
2.4 Co-morbidities and Complications 14
2.5 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 14
2.5.1 Atopic Dermatitis 15
2.5.2 Acne Vulgaris 16
2.5.3 Psoriasis 16
2.6 Treatment 17
2.6.1 Topical Corticosteroids 18
2.6.2 Calcineurin Inhibitors 19
2.6.3 Retinoids 19
2.6.4 Systemic Immunosuppressive Agents 20
2.6.5 Biologics 20
2.6.6 Antihistamines 21
2.6.7 Hormonal Therapy 21
2.6.8 Moisturizers 21
3 Key Marketed Products 23
3.1 Overview 23
3.2 Humira (adalimumab) 24
3.3 Remicade (infliximab) 26
3.4 Enbrel (etanercept) 27
3.5 Stelara (ustekinumab) 29
3.6 Neoral (cyclosporine) 30
3.7 Protopic (tacrolimus) 32
3.8 Elidel (pimecrolimus) 33
3.9 Elocon (mometasone furoate) 34
3.10 Differin (adapalene) 35
3.11 Metolate (methotrexate) 36
3.12 Clobex (clobetasol propionate) 36
3.13 Conclusion 37
3.1 Overview 23
3.2 Humira (adalimumab) 24
3.3 Remicade (infliximab) 26
3.4 Enbrel (etanercept) 27
3.5 Stelara (ustekinumab) 29
3.6 Neoral (cyclosporine) 30
3.7 Protopic (tacrolimus) 32
3.8 Elidel (pimecrolimus) 33
3.9 Elocon (mometasone furoate) 34
3.10 Differin (adapalene) 35
3.11 Metolate (methotrexate) 36
3.12 Clobex (clobetasol propionate) 36
3.13 Conclusion 37
4 Pipeline Landscape Assessment 38
4.1 Overview 38
4.2 Molecule Types in the Pipeline 41
4.3 Molecular Targets in the Pipeline 43
4.4 Clinical Trials 44
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 45
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 48
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 52
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 56
4.5 Conclusion 61
4.1 Overview 38
4.2 Molecule Types in the Pipeline 41
4.3 Molecular Targets in the Pipeline 43
4.4 Clinical Trials 44
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 45
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 48
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 52
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 56
4.5 Conclusion 61
5 Multi-Scenario Market Forecast to 2022
62
5.1 Overall Market Size 62
5.2 Generic Penetration 63
5.3 Revenue Forecast by Molecular Target 65
5.3.1 Tumor Necrosis Factor-Alpha 65
5.3.2 Interleukins 1, 4, 5, 12, 17 and 23 and Receptors 66
5.3.3 Calcineurin 67
5.3.4 Glucocorticoid Receptors 68
5.3.5 Phosphodiesterase 4 69
5.3.6 Revenue and Market Share Analysis by Company 70
5.3.7 Assessment of Key Pipeline Products 80
5.1 Overall Market Size 62
5.2 Generic Penetration 63
5.3 Revenue Forecast by Molecular Target 65
5.3.1 Tumor Necrosis Factor-Alpha 65
5.3.2 Interleukins 1, 4, 5, 12, 17 and 23 and Receptors 66
5.3.3 Calcineurin 67
5.3.4 Glucocorticoid Receptors 68
5.3.5 Phosphodiesterase 4 69
5.3.6 Revenue and Market Share Analysis by Company 70
5.3.7 Assessment of Key Pipeline Products 80
6 Company Analysis and Positioning 88
6.1 Company Landscape 89
6.2 Marketed and Pipeline Portfolio Analysis 90
6.1 Company Landscape 89
6.2 Marketed and Pipeline Portfolio Analysis 90
7 Strategic Consolidations 93
7.1 Licensing Deals 93
7.1.1 Deals by Region, Year and Value 93
7.1.2 Deals by Stage of Development and Value 95
7.1.3 Deals by Molecule Type, Mechanism of Action and Value 96
7.1.4 Table for Licensing Deals Valued Above $100m 98
7.2 Co-development Deals 99
7.2.1 Deals by Region, Year and Value 99
7.2.2 Deals by Stage of Development and Value 100
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 101
7.2.4 Table for Co-development Deals Valued Above $100m 103
7.1 Licensing Deals 93
7.1.1 Deals by Region, Year and Value 93
7.1.2 Deals by Stage of Development and Value 95
7.1.3 Deals by Molecule Type, Mechanism of Action and Value 96
7.1.4 Table for Licensing Deals Valued Above $100m 98
7.2 Co-development Deals 99
7.2.1 Deals by Region, Year and Value 99
7.2.2 Deals by Stage of Development and Value 100
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 101
7.2.4 Table for Co-development Deals Valued Above $100m 103
8 Appendix 104
8.1 References 104
8.2 Table of Epidemiology Forecast 109
8.3 Table of All Clinical Stage Pipeline Products 110
8.4 Abbreviations 141
8.5 Disease List 142
8.6 Methodology 142
8.6.1 Coverage 142
8.6.2 Secondary Research 142
8.6.3 Market Size and Revenue Forecasts 143
8.6.4 Pipeline Analysis 143
8.6.5 Competitive Landscape 143
8.1 References 104
8.2 Table of Epidemiology Forecast 109
8.3 Table of All Clinical Stage Pipeline Products 110
8.4 Abbreviations 141
8.5 Disease List 142
8.6 Methodology 142
8.6.1 Coverage 142
8.6.2 Secondary Research 142
8.6.3 Market Size and Revenue Forecasts 143
8.6.4 Pipeline Analysis 143
8.6.5 Competitive Landscape 143
Comments
Post a Comment